menu
    • menu

    Company profile for OSE Immunotherapeutics SA

    NEW Drugs in Dev: 11
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company utilizes several scientific and technological approaches including neoepitopes and agonist/antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Our first-in-class pipeline offers a diver...
    OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company utilizes several scientific and technological approaches including neoepitopes and agonist/antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Our first-in-class pipeline offers a diversified risk profile, ranging from registrational to clinical stage to R&D.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OSE Immunotherapeutics SAFrance Flag
    Country
    Country
    France
    Address
    Address
    22, boulevard Benoni Goullin \n44200 Nantes
    Telephone
    Telephone
    33 (0) 2 28 29 10 10
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ose-immuno.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ose-immunotherapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/OSEIMMUNO

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OSE Immunotherapeutics Picks Lusvertikimab for Chronic Diseases
    OSE Immunotherapeutics Picks Lusvertikimab for Chronic Diseases

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228188/0/en/OSE-Immunotherapeutics-Selects-Chronic-Pouchitis-and-Hidradenitis-Suppurativa-as-New-Key-Indications-for-Lusvertikimab.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    OSE Immunotherapeutics Welcomes FDA Orphan Designation
    OSE Immunotherapeutics Welcomes FDA Orphan Designation

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3223109/0/en/OSE-Immunotherapeutics-Welcomes-FDA-Orphan-Drug-Designation-Granted-to-Pegrizeprument-VEL-101.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Half-Year Liquidity Contract Report: Invest Securities
    Half-Year Liquidity Contract Report: Invest Securities

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3222106/0/en/Half-Year-Report-on-Liquidity-Contract-with-Invest-Securities.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    OSE Immuno Announces Strategic Amendment to AbbVie
    OSE Immuno Announces Strategic Amendment to AbbVie

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201201/0/en/OSE-Immunotherapeutics-Announces-Strategic-Amendment-to-AbbVie-s-Partnership-on-ABBV-230-Development.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan
    OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202055/0/en/OSE-Immunotherapeutics-Unveils-2026-2028-Strategic-Plan-With-Four-Opportunities-for-Value-Creation.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    OSE Immunotherapeutics Gets (IDMC) Nod To Proceed Tedopi Ph 3
    OSE Immunotherapeutics Gets (IDMC) Nod To Proceed Tedopi Ph 3

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189428/0/en/OSE-Immunotherapeutics-Announces-Positive-Recommendation-from-Independent-Data-Monitoring-Committee-IDMC-to-Continue-Pivotal-Phase-3-ARTEMIA-Trial-Evaluating-Tedopi-in-Non-Small-Ce.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search